Arctic Bioscience Q3 2021 Operational Update
· Psoriasis phase IIb study for HRO350 on track: site feasibility process ongoing in Europe as planned with positive response from sites with access to patients for H1 2022. · New GMP manufacturing facility in Ørsta: Building process commenced, with planned finalization H2 2023. In-house manufacturing of our nutraceutical and investigational pharmaceutical products is expected to significantly improve company-wide gross margins. · Full year adjusted EBITDA forecast in expected range of NOK -25 to -30 million · Year-end cash position remains very solid, forecast in the range of NOK